Details for Patent: 9,216,969
✉ Email this page to a colleague
Which drugs does patent 9,216,969 protect, and when does it expire?
Patent 9,216,969 protects ORKAMBI and is included in two NDAs.
Protection for ORKAMBI has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.
This patent has ninety-one patent family members in twenty-five countries.
Summary for Patent: 9,216,969
| Title: | Modulators of ATP-binding cassette transporters |
| Abstract: | Compounds of the present invention, and pharmaceutically acceptable compositions thereof, are useful as modulators of ATP-Binding Cassette (“ABC”) transporters or fragments thereof, including Cystic Fibrosis Transmembrane Conductance Regulator (“CFTC”). The present invention also relates to methods of treating ABC transporter mediated diseases using compounds of the present invention. |
| Inventor(s): | Sara S. Hadida Ruah, Matthew Hamilton, Mark Miller, Peter D. J. Grootenhuis, Brian Bear, Jason McCartney, Jinglan Zhou |
| Assignee: | Vertex Pharmaceuticals Inc |
| Application Number: | US13/871,364 |
|
Patent Claim Types: see list of patent claims | Composition; Compound; |
More… ↓ |
Drugs Protected by US Patent 9,216,969
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Vertex Pharms Inc | ORKAMBI | ivacaftor; lumacaftor | GRANULE;ORAL | 211358-003 | Sep 2, 2022 | RX | Yes | No | ⤷ Start Trial | ⤷ Start Trial | Y | ⤷ Start Trial | ||||
| Vertex Pharms Inc | ORKAMBI | ivacaftor; lumacaftor | GRANULE;ORAL | 211358-001 | Aug 7, 2018 | RX | Yes | No | ⤷ Start Trial | ⤷ Start Trial | Y | ⤷ Start Trial | ||||
| Vertex Pharms Inc | ORKAMBI | ivacaftor; lumacaftor | GRANULE;ORAL | 211358-002 | Aug 7, 2018 | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | Y | ⤷ Start Trial | ||||
| Vertex Pharms Inc | ORKAMBI | ivacaftor; lumacaftor | TABLET;ORAL | 206038-002 | Sep 28, 2016 | RX | Yes | No | ⤷ Start Trial | ⤷ Start Trial | Y | ⤷ Start Trial | ||||
| Vertex Pharms Inc | ORKAMBI | ivacaftor; lumacaftor | TABLET;ORAL | 206038-001 | Jul 2, 2015 | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | Y | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 9,216,969
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| European Patent Office | 2404919 | ⤷ Start Trial | PA2016015 | Lithuania | ⤷ Start Trial |
| European Patent Office | 2404919 | ⤷ Start Trial | 93073 | Luxembourg | ⤷ Start Trial |
| European Patent Office | 2404919 | ⤷ Start Trial | CA 2016 00019 | Denmark | ⤷ Start Trial |
| European Patent Office | 2395002 | ⤷ Start Trial | 300812 | Netherlands | ⤷ Start Trial |
| European Patent Office | 2404919 | ⤷ Start Trial | 16C0020 | France | ⤷ Start Trial |
| European Patent Office | 2404919 | ⤷ Start Trial | C20160015 00195 | Estonia | ⤷ Start Trial |
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
